Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Torhout – page 73

2 086 clinical trials in Torhout, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Torhout at a glance
2 086
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

2 086 trials in Torhout

Open in trial search

Renal disorder

Not yet recruiting

Study of Surovatamig and Human IgG4 Kappa Monoclonal Antibody Against CD3 and CD19 in Adults with Antibody-Mediated Kidney Disease

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Human Igg4 Kappa Monoclonal Antibody Against Cd3 And Cd19
  • Sponsor:AstraZeneca AB

Colon cancer

Not yet recruiting

Neoadjuvant Pembrolizumab and Porustobart for Resectable pMMR/MSS Colon Cancer: A Phase 2 Study of Efficacy and Safety in Eligible Patients

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Solstice Oncology Inc.

Pulmonary hypertension

Not yet recruiting

Phase 3 Trial Evaluating Inhaled Mosliciguat for Safety, Efficacy, and Exercise Capacity in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Mosliciguat
  • Sponsor:Pulmovant Inc.

Colitis ulcerative+1

Not yet recruiting

Study of risankizumab plus anti‑α4β7 integrin antibody versus each alone in adults with moderately to severely active Crohn’s disease or ulcerative colitis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Endometrial cancer

Not yet recruiting

Maintenance Treatment Study of gsk5733584 with dostarlimab or pembrolizumab in patients with mismatch repair proficient advanced or recurrent endometrial cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Glaxosmithkline Research & Development Limited

COVID-19+1

Not yet recruiting

Safety and immune response of investigational mRNA vaccine GSKVX000000078664 versus drug combination in adults with flu and COVID-19

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Elasomeran
  • Sponsor:GlaxoSmithKline Biologicals

Urinary tract infection

Not yet recruiting

A study of fosfomycin trometamol treatment for male urinary tract infections in primary care settings

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fosfomycin Trometamol
  • Sponsor:Centre Hospitalier Universitaire Rouen

Transitional cell carcinoma

Not yet recruiting

Neoadjuvant Study of Avelumab with Gemcitabine and Cisplatin versus Chemotherapy Alone in Patients with High‑Grade Localized Upper Tract Urothelial Carcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Centre Hospitalier Universitaire De Nimes

Immune response and safety of revaccination with respiratory syncytial virus glycoprotein F recombinant vaccine adjuvanted with AS01E in older adults

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:65+ years · Healthy volunteers
  • Substances:GSKVx000000017064
  • Sponsor:GlaxoSmithKline Biologicals

Ravulizumab versus plasma exchange for acute neuromyelitis optica attacks: a randomized trial in patients with first or relapsed episodes

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ravulizumab
  • Sponsor:Les Hopitaux Universitaires De Strasbourg

Antiphospholipid syndrome

Not yet recruiting

Stopping warfarin sodium, fluindione, or acenocoumarol in low‑risk thrombotic antiphospholipid syndrome patients after antibody loss

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Acenocoumarol
  • Sponsor:Assistance Publique Hopitaux De Paris

Partial seizures

Not yet recruiting

Phase 3 Randomized Study of RAP-219 to Reduce Seizure Frequency in Adults with Focal Epilepsy

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:Rapport Therapeutics Inc.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Torhout

What the registry says about research in the country

01 Dermatology Research

Innovative clinical research focusing on severe alopecia areata, evaluating a novel oral medication's effectiveness in treating this autoimmune hair loss condition. The trials aim to assess long-term safety and efficacy of different dosing strategies.

  • Hair Loss Treatment
  • Autoimmune Conditions
  • Long-term Treatment Evaluation

Studies include both adult and adolescent participants, exploring various treatment durations and response patterns.

02 Oncology Research

Groundbreaking studies in Non-Small Cell Lung Cancer treatment, comparing therapeutic cancer vaccines with traditional chemotherapy approaches in patients who have undergone prior immunotherapy.

  • Advanced Lung Cancer
  • Immunotherapy
  • Therapeutic Vaccines

Research specifically targets HLA-A2 positive patients with metastatic disease, focusing on survival outcomes.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.